At a glance
- Originator Taisho Pharmaceutical
- Class Antibacterials; Macrolides
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 20 Jul 1998 No-Development-Reported for Bacterial infections in Japan (PO)
- 16 Oct 1995 Preclinical development for Bacterial infections in Japan (PO)